ClinicalTrials.gg
Active, not recruitingNCT05857137Updated Sep 11, 2026

Psychosis TMS Study

An interventional study of Active TMS and Placebo TMS in Psychosis, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Psychotic Disorders by Massachusetts General Hospital — 4 open to participants now, 6 under way, none of them phase 3. Psychotic Disorders · Massachusetts General Hospital.

Planned enrollment
14th of 15
20 · median 65
Started
2023
the only one that year
No phase
9 of 15
4 open now
Registered
10th of 15
by date

Among the 15 studies in Psychotic Disorders by Massachusetts General Hospital, this one is the 14th largest by planned enrollment, is the only one that started in 2023, is one of 9 with no phase, and was the 10th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

4 of the 15 studies in Psychotic Disorders by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Psychotic Disorders by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The main goal of this study is to investigate the neural mechanisms of working memory function in patients with early psychosis using Transcranial Magnetic Stimulation (TMS) in conjunction with functional MRI. TMS is a noninvasive method used to modulate brain activity via changing magnetic fields applied over the surface of the scalp.

03

Conditions studied

  • Psychosis

Keywords

  • Cognitive impairment
  • Transcranial Magnetic Stimulation
  • Attention
  • Short-term memory
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of psychosis, psychosis not otherwise specified, schizophrenia, schizoaffective disorder, delusional disorder, bipolar disorder with psychosis, and schizophreniform disorder within first ten years of onset of psychotic symptoms.
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • TMS incompatibility including metallic implants in head and neck, cardiac pacemakers, history of seizures, pregnancy.
  • MRI-incompatibility including implanted aneurism clips, cardiac pacemakers, metal implants, intrauterine devices, tattoos containing metal ink, pregnancy, and claustrophobia
  • Severe substance abuse within 3 months (nicotine allowed)
  • Unstable medical or neurologic illness that would preclude participation in study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Active TMS

    Participants will receive single-session administration of TMS. Functional MRI will be acquired before and immediately after the intervention.

    Device: Active TMS

  • Placebo comparator
    Placebo TMS

    Participants will also receive single session administration of placebo TMS (at least two days apart from the day of the active TMS). Functional MRI will be acquired before and immediately after the intervention.

    Device: Placebo TMS

Interventions

  • DeviceActive TMS

    Continuous theta burst stimulation (cTBS) will be administered over the left inferior parietal lobule for approximately 3 minutes at 120% of the resting motor threshold.

  • DevicePlacebo TMS

    Placebo TMS will be applied over the left inferior parietal lobule for approximately 3 minutes.

06

What researchers measure

Primary outcomes

  1. Working memory accuracy

    Accuracy at high memory loads during performance of the Sternberg Item Recognition Paradigm will be assessed before and after the TMS interventions.

    Time frame: 2 hours

  2. Reaction time during working memory

    Reaction time during performance of the Sternberg Item Recognition Paradigm will be assessed before and after the TMS interventions.

    Time frame: 2 hours

  3. Resting state functional connectivity between the left inferior parietal lobule and the regions of the frontoparietal control network

    Functional connectivity between left inferior parietal lobule and dorsolateral prefrontal cortex will be computed during resting state acquired before and after the TMS interventions.

    Time frame: 2 hours

  4. Resting state functional connectivity within the default mode network

    Functional connectivity between left inferior parietal lobule and other regions of the default mode network (including the posterior cingulate cortex and the medial prefrontal cortex) will be computed during resting state acquired before and after the TMS interventions.

    Time frame: 2 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Nov 2026, 43 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 43 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2023
First posted
May 12, 2023
StartActual
Apr 4, 2023
Primary completionEst.
Nov 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05857137
Responsible party
Hamdi Eryilmaz, PhD (Assistant Professor, Massachusetts General Hospital) — Principal investigator
First posted
May 12, 2023
Start date
Apr 4, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion